pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 12·1 min read
save

Alcohol screening often skipped in primary care, raising health costs

May 12, 2026·read at STAT ↗Negative

Doctors are expected to ask patients about their alcohol consumption during routine checkups, but many primary care visits omit or rush this conversation.

Evidence-based screening tools can be applied within a typical 15-minute appointment, yet studies show the process is frequently compressed or left out entirely.

The resulting gap not only leaves patients without needed support for unhealthy drinking but also adds substantial costs to the health-care system.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Despite its toll, alcohol is still an awkward subject in the doctor’s office”

read at STAT ↗
523 words · retrieved May 12
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING2
topics
Hepatology3Immunology2HypertensionOncology

related stories

  • 3d agoCaribou layoffs could wipe out 90% of staffBioSpace
  • 3d agoTRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering termsBioSpace
  • 5d agoGenmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreBioSpace
  • 6d agoTRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go publicFierce Biotech
  • Oct 2BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBioSpace